These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29069808)

  • 1. Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC.
    MacDonagh L; Gallagher MF; Ffrench B; Gasch C; Breen E; Gray SG; Nicholson S; Leonard N; Ryan R; Young V; O'Leary JJ; Cuffe S; Finn SP; O'Byrne KJ; Barr MP
    Oncotarget; 2017 Sep; 8(42):72544-72563. PubMed ID: 29069808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin.
    MacDonagh L; Santiago RM; Gray SG; Breen E; Cuffe S; Finn SP; O'Byrne KJ; Barr MP
    Transl Oncol; 2021 Apr; 14(4):101025. PubMed ID: 33550205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastasis-associated in colon cancer-1 and aldehyde dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer.
    Zhou L; Yu L; Zhu B; Wu S; Song W; Gong X; Wang D
    BMC Cancer; 2016 Nov; 16(1):876. PubMed ID: 27832750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of ALDH1 activity in rabbit hepatic VX2 tumors and isolation of ALDH1 positive cancer stem cells.
    Gehlot P; Shukla V; Gupta S; Makidon PE
    J Transl Med; 2016 Feb; 14():49. PubMed ID: 26873175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiles of prostate cancer stem cells isolated by aldehyde dehydrogenase activity assay.
    Nishida S; Hirohashi Y; Torigoe T; Kitamura H; Takahashi A; Masumori N; Tsukamoto T; Sato N
    J Urol; 2012 Jul; 188(1):294-9. PubMed ID: 22608744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ALDH1⁺ subpopulation of the human NMFH-1 cell line exhibits cancer stem-like characteristics.
    Li D; Zhang T; Gu W; Li P; Cheng X; Tong T; Wang W
    Oncol Rep; 2015 May; 33(5):2291-8. PubMed ID: 25760144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
    Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
    Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of aldehyde dehydrogenase 1 expression defines a group with better prognosis in patients with non-small cell lung cancer.
    Dimou A; Neumeister V; Agarwal S; Anagnostou V; Syrigos K; Rimm DL
    Am J Pathol; 2012 Oct; 181(4):1436-42. PubMed ID: 22877687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics.
    Shao J; Fan W; Ma B; Wu Y
    Mol Med Rep; 2016 Dec; 14(6):4991-4998. PubMed ID: 27840965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy.
    Shien K; Toyooka S; Ichimura K; Soh J; Furukawa M; Maki Y; Muraoka T; Tanaka N; Ueno T; Asano H; Tsukuda K; Yamane M; Oto T; Kiura K; Miyoshi S
    Lung Cancer; 2012 Jul; 77(1):162-7. PubMed ID: 22387005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo expression of aldehyde dehydrogenase 1 in oral squamous cell carcinoma.
    Ota N; Ohno J; Seno K; Taniguchi K; Ozeki S
    Int J Oncol; 2014 Feb; 44(2):435-42. PubMed ID: 24285422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling.
    Su J; Wu S; Tang W; Qian H; Zhou H; Guo T
    Mol Carcinog; 2016 Nov; 55(11):1822-1832. PubMed ID: 26513225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical and prognostic impact of aldehyde dehydrogenase 1 in non-small cell lung cancer: a meta-analysis.
    Xue J; Zhao Y; Zou Q; Liang F; Lin F
    Transl Cancer Res; 2020 Mar; 9(3):1914-1925. PubMed ID: 35117538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DCLK1 Regulates Tumor Stemness and Cisplatin Resistance in Non-small Cell Lung Cancer via ABCD-Member-4.
    Panneerselvam J; Mohandoss P; Patel R; Gillan H; Li M; Kumar K; Nguyen D; Weygant N; Qu D; Pitts K; Lightfoot S; Rao C; Houchen C; Bronze M; Chandrakesan P
    Mol Ther Oncolytics; 2020 Sep; 18():24-36. PubMed ID: 32637578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma.
    Flahaut M; Jauquier N; Chevalier N; Nardou K; Balmas Bourloud K; Joseph JM; Barras D; Widmann C; Gross N; Renella R; Mühlethaler-Mottet A
    BMC Cancer; 2016 Oct; 16(1):781. PubMed ID: 27724856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
    Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
    Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
    Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-129-5p inhibits non-small cell lung cancer cell stemness and chemoresistance through targeting DLK1.
    Ma Z; Cai H; Zhang Y; Chang L; Cui Y
    Biochem Biophys Res Commun; 2017 Aug; 490(2):309-316. PubMed ID: 28619508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.